218 episodes

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

Lung Cancer Considered IASLC

    • Science
    • 4.5 • 20 Ratings

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

    Best Practice for RET NSCLC

    Best Practice for RET NSCLC

    Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quickly. He is joined on the podcast by Dr. Oliver Gautschi from the University of Bern and Cancer Center Lucerne in Switzerland and Dr. Mihaela Aldea from Gustave Roussy in France.

    • 34 min
    Biomarkers in Lung Cancer: Barriers to Implementation

    Biomarkers in Lung Cancer: Barriers to Implementation

    Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of evidence-based guidelines for these tests. To discuss the importance of this survey and its underlying issues, host Dr. Stephen Liu discusses some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer. To take the survey, visit: https://bit.ly/BiomarkerS24

    • 45 min
    LCC in Cantonese Chinese: Barriers to Biomarker Testing

    LCC in Cantonese Chinese: Barriers to Biomarker Testing

    Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li. To take the survey, visit: https://bit.ly/BiomarkerS24

    • 39 min
    LCC in Mandarin Chinese: Barriers to Biomarker Testing

    LCC in Mandarin Chinese: Barriers to Biomarker Testing

    Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li. To take the survey, visit: https://bit.ly/BiomarkerS24

    • 28 min
    LCC in French Canadian: Barriers to Biomarker Testing

    LCC in French Canadian: Barriers to Biomarker Testing

    Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Norman Blais moderates a discussion about biomarker testing in French Canadian with Dr. Arielle Elkrief and Dr. Nicolas Marcoux. To take the survey, visit: https://bit.ly/BiomarkerS24

    • 45 min
    LCC in French: Barriers to Biomarker Testing

    LCC in French: Barriers to Biomarker Testing

    Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for biomarker tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol. To take the survey, visit: https://bit.ly/BiomarkerS24

    • 39 min

Customer Reviews

4.5 out of 5
20 Ratings

20 Ratings

TBobo ,

Episode on Immunotherapy

Really enjoyed the conversation between these oncologist. They seem to be great doctors who really care for their patients are working for the best solutions they know of.

It was also interesting to see their blind spots. The great thing about immunotherapy is slowly opening the door between integrative oncology and traditional oncology. These guys don’t get into it but they are asking the right questions.

1) What can be combined with immunotherapy?
2) What can be done to prevent side effects of traditional treatment?
3) What things can be done to both enhance traditional treatments and lower side effects?

Naturopath and integrative doctors know many possible answer to these questions based on case studies and their personal experience. Things that will never get a $500 million dollar set of clinical trials, but have worked for patient after patient.

- Infrared Saunas to detox from chemo and have much fewer side effects (combined with other detox techniques).
- High Dose Melatonin to reduce radiation damage - with early limited clinical trials as evidence.
- Hypothermia for combining with immunotherapy.
- Proton radiation on a different schedule than normal to promote immunotherapy (3 day on 4 day off cycle seems to work better than the traditional 5 day on 2 day off, to give the immune system a chance to do its thing).
- Micro-biome research to enhance immunotherapy both through diet, supplements, and even fecal transplants.
- Natural products and off-label drugs to help limit the metabolism of cancer to slow down its growth, keep it from mutating to new food sources, and ultimately make chemo and other treatments more effective, as well as providing a much greater quality of life for the patients.

If transitional oncology would do two things, immunotherapy will advance much faster.
1) Eat a bite of humble pie and realize integrative doctors and oncologist have some answers, and start having conversations with them.
2) Realize their training and education failed them in the areas of nutrition, health, and epi-genetics.
3) Realize the level of corruption in the FDA, NIH, and pharmaceutical companies, with at least 350 MILLION dollars being passed under the table to individual for the last 10 years. This seems to be greatly hampering the rules being used to approve new drugs - creating measure that have nothing to do with patient survival - but do help big pharma profits. So after realizing there is this level of corruption and unethical behavior, it is illogical and unethical to continue to just rely on these groups to produce the “cures” for cancer.

It is going to take people doing and trying things have have more ethical motivations, writing papers, doing smaller trials, and forcing innovation solutions down the throat of the FDA with them kicking an screaming.

Then someone needs to do something to STOP the unethical price gouging of the Pharma on immunotherapy. The are obviously coordinating their pricing in a cornered market. Again unethical and unjustified. We need to vote for political leaders who can pass some laws to bring this into account.

And all the Cancer patient advocacy groups that are SILENT on these issues need to be shamed into action… even though they get big donations from big Pharma too.

DrFLC ,

Fantastic for doctors, nurses, patients

Great conversations on all things lung cancer.

yeoohaz ,

:)

great info!

Top Podcasts In Science

Hidden Brain, Shankar Vedantam
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
WNYC Studios
Alie Ward
Neil deGrasse Tyson
Sam Harris

You Might Also Like

Sam and Karine
Vinay Prasad, MD MPH
NEJM Group
Sensible Medicine Authors - Prasad/Cifu/Mandrola/Demania/Makary/Cristea/Alderighi & More
JAMA Network
JAMA Network